a:7:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”page”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;}
a:8:{s:8:”location”;a:1:{i:0;a:1:{i:0;a:3:{s:5:”param”;s:9:”post_type”;s:8:”operator”;s:2:”==”;s:5:”value”;s:4:”page”;}}}s:8:”position”;s:6:”normal”;s:5:”style”;s:7:”default”;s:15:”label_placement”;s:3:”top”;s:21:”instruction_placement”;s:5:”label”;s:14:”hide_on_screen”;s:0:””;s:11:”description”;s:0:””;s:12:”show_in_rest”;b:0;}
Fount Bio, Inc. is pleased to announce the appointment of Dan Browne as an independent Director to Fount Bio’s Board of Directors. Dan joins current board members Anthony Aiudi and Justin Burns from Morningside Ventures and co-founders Samir Mitragotri and Douglas Levinson.
Dan Browne has more than 30 years of entrepreneurial and executive leadership experience in the healthcare industry. He has led the development of multiple innovative products that are leaders in their category, as well as critical business development and partnership activities. Dan is the co-founder and former CEO of Revance Therapeutics, Inc. He brought the company from early-stage incubator in 2002 to a highly successful IPO in 2014. During Dan’s tenure at Revance, all the core R&D, clinical, regulatory/quality, finance and commercial operations reported to him.
“We are honored to have Dan join our Board. Dan brings outstanding knowledge and experience to Fount Bio and will strengthen our efforts to translate our Flī-HA (functional ligand hyaluronic acid) platform technology for topical delivery of hyaluronic acid (HA) into exciting, category leading products.” said Douglas Levinson, Founder and CEO, Fount Bio. “Dan’s expertise in bringing early-stage innovation all the way through the necessary steps to commercial readiness and successful IPO will be extraordinarily valuable as we grow Fount Bio.”
“I am excited about the opportunity that Fount Bio and the Flī-HA platform represent. There is significant unmet need for a novel, tailored and targeted topical delivery mechanism for hyaluronic acid.” said Dan Browne. “The robust scientific expertise, data generated to date and the pedigree of the Fount Bio leadership team gives me confidence in what they have and the potential breakthrough in the delivery of hyaluronic acid. I am looking forward to supporting them on that journey.”
Fount Bio is currently developing its novel and proprietary Flī-HA for aesthetics and dermatological use while also exploring product opportunities across a range of high potential market categories where Flī-HA provides important and distinct advantages. Currently, marketed HA-based products encompass a broad range of high-value commercial opportunities. In the medical aesthetics area alone, the current market for HA injectables is expected to approach $6B by 2025. Flī-HA-based products have the potential to grow and capture market share even further by providing a topical alternative to injection.
About Flī-HA, the first of its kind technology
Fount Bio’s proprietary Flī-HA (functional ligand-hyaluronic acid) platform is the world’s first platform designed to build a biostable HA matrix where it’s needed. It’s based on natural biochemical reactions that occur within living systems. As a result, Flī-HA technology overcomes longstanding delivery and biostability challenges of large glycoproteins like HA and enables HA to be topically delivered either on tissue surfaces or deeper, where it’s retained for extended periods.
About Fount Bio
Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary glycopolymer technology that combines proprietary innovations in biorthogonal chemistry and glycopolymer science. Fount Bio’s Flī- technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. Our Flī-HA platform technology delivers hyaluronic acid, a naturally occurring and necessary component present in various tissues throughout the body, including skin, eyes, joints and mucosa. For more information, visit www.fountbio.com
Fount Bio, Inc. successfully closed a Series A round of financing led by Morningside Ventures. This initial investment will be focused on progressing Fount Bio’s, Flī-HA (functional ligand hyaluronic acid) technology forward into clinical evaluation for aesthetic and dermatological indications. Anthony Aiudi and Justin Burns from Morningside Ventures will be joining founders Samir Mitragotri and Doug Levinson on Fount’s Board of Directors.
“We are thrilled to come in at this early stage and support development of Fount Bio’s Flī-HA platform technology and their lead product concept. Our focus is on supporting compelling and novel innovations that have the potential to change the category or treatment paradigm. We have a strong track record of breakthrough and FastTrack programs under our belt and we feel that the innovation being developed by Fount Bio in Flī-HA has the potential to follow suit.” Anthony Aiudi, Morningside Ventures.
Hyaluronic Acid (HA), is a naturally occurring component that serves a key role in various tissues throughout the body, including skin, eyes, joints and mucosa. Topical delivery of HA into tissues like skin has been long sought after but has not been possible to date given the large size of HA. Flī-HA technology overcomes longstanding delivery and biostability challenges associated with large HA glycopolymers and enables them to be topically delivered – either onto tissue surfaces or deeper within tissues – and with long duration retention.
“I am extremely excited about our partnership with Morningside Ventures and their longstanding commitment to supporting and advancing development of novel high-impact products based on breakthrough technologies. The Morningside team brings tremendous value to Fount Bio and enables us to translate our proprietary hyaluronic acid (HA) Flī-HA platform technology into exciting and innovative new products. The unmet need for targeted, topical HA delivery presents a real opportunity and we hope to demonstrate the potential in aesthetics and dermatology as well as future categories as we further the development of Flī-HA” – Douglas Levinson, Fount Bio Founder and CEO
Fount Bio’s initial focus is to develop Flī-HA-based products for the aesthetics, medical dermatology, and consumer beauty markets. In the medical aesthetics area alone, HA-based injectable products generate sales approaching $6B annually.
Beyond the initial focus on aesthetic and medical dermatology applications, Fount Bio is exploring development of products across a range of high potential market categories where Flī-HA can provide important and distinct advantages.
About Morningside Ventures
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com
About Fount Bio
Fount Bio is a life science company developing a pipeline of innovative products for medical and beauty applications based on proprietary biopolymer technology that combines proprietary innovations in biorthogonal chemistry and biopolymer science. Fount Bio’s Flī- technology platform represents a novel approach to overcome key challenges associated with delivery of large glycopolymers like HA, allowing tailored placement onto tissue surfaces or within tissues where they are retained for extended periods of time. Our Flī-HA platform technology delivers Hyaluronic Acid (HA), a naturally occurring and necessary component present in various tissues throughout the body, including skin, eyes, joints and mucosa. For more information visit www.fountbio.com
Fount Bio, Inc.
325 Vassar St, Suite 2A
Cambridge, MA 02139
info@fountbio.com
© 2022 Fount Bio, Inc.
We use cookies to understand site usage and to improve user experience. Please click the “Accept” button or continue to use the site if you agree to the use of cookies and our Privacy Policy.
AcceptWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.